Novo Nordisk shares pop 10% on early-stage weight loss drug trial results

Company Performance - Shares of Novo Nordisk jumped 9 5% at 11 02 a m London time following positive early-stage results for its once weekly amycretin obesity drug [1] - The trial showed an average weight reduction of 22% in obese and overweight patients after 36 weeks [1] Product Development - Novo Nordisk reported positive early-stage results for its once weekly amycretin obesity drug [1] - The drug demonstrated significant efficacy with a 22% average weight reduction in obese and overweight patients over 36 weeks [1]